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Michael A. Maddaus, MDEndobronchial ultrasonography with transbronchial needle
aspiration biopsy (EBUS-TBNA) has gained acceptance as
an alternative to mediastinoscopy to diagnose and stage
non–small cell lung cancer (NSCLC).1,2 Once a decision
has been made to obtain biopsy specimens of mediastinal
lymph nodes (MLNs), the choice of biopsy technique
gains importance. However, despite the extensive
experience with EBUS-TBNA in many centers, one must
keep in mind that the Achilles’ heel of EBUS-TBNA is
the greater variability in negative predictive value (NPV)
compared with mediastinoscopy (EBUS-TBNA NPV ¼
60%-99%; mediastinoscopy NPV ¼ 80%-99%), generat-
ing an increased concern for false negative results. Because
false negative findings can have a major detrimental impact
on patient outcomes, the physician performing EBUS-
TBNA must use the best single procedure or combination
of techniques to ensure the most accurate results of medias-
tinal staging.
WHAT IS THE ROLE OF EBUS-TBNA IN STAGING
NSCLC?
Once a decision has been made to pathologically stage
the mediastinum in a patient with suspected or confirmed
NSCLC, the role of EBUS-TBNA will be determined by
a variety of factors. The diagnostic performance of the
test will depend on the pretest probability of N2 disease,
physician skills, quality and evaluation skills of the sample
by a cytopathologist, and the clinician’s interpretation of the
results.
Pretest Probability
Inasmuch as not all patients with NSCLC will have the
same probability of positive N2 MLNs, the implications
of an imperfect NPV are variable. The main concern for
clinicians is the possibility of understaging a patient’s dis-
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The Journal of Thoracic and Csuboptimal treatment. In patients with a low pretest prob-
ability of N2 disease, the likelihood of a false negative re-
sult is low. In general, in these patients a negative result is
sufficiently reliable to guide further treatment decisions.
However, if a patient’s probability of N2 disease is
higher, as in a patient with a large and/or centrally located
tumor, then the less than optimal NPV may warrant much
greater caution in clinical decision making. We have de-
signed a schematic for the role of EBUS-TBNA in
NSCLC staging based on pretest probability (Figures 1
and 2). Scans are shown in Figures 1, B and C and
Figures 2, B and C.Physician EBUS Skills
Physician EBUS skills are determined by an individ-
ual’s technical skills and by his or her level of under-
standing of the impact of an inaccurate MLN biopsy
on the outcome of a patient with NSCLC. It is essential
to realize that published results on EBUS-TBNA as
a staging tool in NSCLC mainly come from expert cen-
ters and are not likely to be reproducible in less experi-
enced centers.
Technical skills. The American College of Chest Physi-
cians3 recommends that 50 EBUS procedures be required
to prove proficiency. Although the technical skills required
for identifying and sampling enlarged MLNs are quite
basic, proficiency in identifying normal-sized MLNs in all
relevant MLN stations requires significantly more experi-
ence and commitment to technical perfection. Much as
with mediastinoscopy, a physician performing EBUS
must sample all relevant MLN stations even if MLNs
have benign ultrasonographic appearance. Ideally, we rec-
ommend that physicians performing EBUS also seek to
achieve proficiency in esophageal endoscopic ultrasound
because the combination of esophageal endoscopic ultra-
sound and EBUS has a higher diagnostic yield than either
procedure alone.4
Understanding of NSCLC. In our opinion, for a physician
to be fully qualified to perform EBUS in a patient with
NSCLC, the physician must function as part of a multidisci-
plinary lung cancer team. Additionally, the physician needs
to be completely familiar with each patient’s clinical pre-
sentation because patient-specific factors may influence
the mediastinal staging algorithm. Finally, the physician
must have experience with management of patients withardiovascular Surgery c Volume 144, Number 3 S9
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EBUS ¼ endobronchial ultrasonography
MLN ¼ mediastinal lymph node
NPV ¼ negative predictive value
NSCLC ¼ non–small cell lung cancer
ROSE ¼ rapid on-site evaluation
TBNA ¼ transbronchial needle aspiration biopsyS10 ThNSCLC to provide the skill and judgment for interpretation
of results and risk stratification.
Quality and Evaluation of the Sample
The clinical applicability and precision of EBUS-TBNA
as a diagnostic tool in NSCLC depends to a great extent on
the quality of the sample and on the cytopathologist’s
skills.5 The role of the cytopathologist is just as important
as the role of the EBUS-TBNA operator.
Quality of the sample. A minimum requirement of cellu-
larity is indispensable to permit cytopathologic interpreta-
tion of an EBUS-TBNA sample.6 The presence of 40
lymphocytes per high-power field in the more cellular areas
of the smear and/or the presence of clusters of pigmented
macrophages are good predictors of the adequacy of a sam-
pled lymph node free of metastasis. In certain cases of nodal
replacement by granulomatous disease, lymphoid tissue
might not be seen in samples that remain satisfactory for
evaluation.
Evaluation of the sample. At our institution, an experi-
enced cytopathologist is always available for rapid on-site
evaluation (ROSE) of samples. We believe real-time com-
munication between the operator and the cytopathologist
is crucial to maximize the yield of the procedure. The cyto-
pathologist can inform the operator within a few minutes
whether a specimen is adequately cellular (see above) or
nondiagnostic (eg, mainly blood or bronchial cells). An ad-
equate sample will then be classified as (1) benign lympho-
cytes, (2) benign pathology (eg, granuloma), or (3)
malignant pathology. The concordance between ROSE
and final cytologic analysis at our institution is 95%.7
However, in our experience of more than 400 EBUS-
TBNA procedures, about 15% of MLN samples continue
to be nondiagnostic.6
If ROSE is not available at an institution, then the
EBUS physician cannot make an intraprocedural decision
regarding the adequacy of sampling. However, if the phy-
sician has a consistent technique, ROSE will probably
not have a significant impact on overall test performance.
The role of ROSE in EBUS-TBNA is to facilitate early
decision making. Although ROSE affects the timing of
the decision, its availability does not affect the decision
itself.e Journal of Thoracic and Cardiovascular SurgClinician’s Interpretation of the Results and Decision
Making
The interpretation of EBUS-TBNA results requires the
clinician’s comprehension of the limitations of the test.
To clearly understand the reliability of EBUS-TBNA in
mediastinal staging in NSCLC, the clinician must under-
stand the importance of the NPV and how NPV should be
determined.
Calculation of the NPVof EBUS-TBNA. The NPV is the
most important measure of test performance for EBUS-
TBNA in patients with lung cancer. The calculation repre-
sents the percentage of patients who will have a negative
test result in the presence of actual disease (false negatives).
Such false negative results can lead to understaging and
suboptimal therapy. We herein review the calculation of
NPV to underscore its importance.
The definition of NPV is as follows:
NPV ¼ True Negatives
True NegativesþFalse Positives
However, when applied to EBUS-TBNA in NSCLC stag-
ing, this definition does not factor in nondiagnostic samples.
Inasmuch as clinicians cannot make treatment decisions on
the basis of nondiagnostic samples, these findings should
probably be added to the NPV denominator.
Our conservative NPV calculation for EBUS-TBNA is as
follows:
NPV ¼ True Negatives
TrueNegativesþFalsePositivesþNondiagnostics
Additionally, this calculation does not take into consider-
ation the pretest probability of N2 disease. The relevance of
a negative or nondiagnostic sample varies with the pretest
probability of N2 disease; we believe that the ‘‘true’’
NPV is probably somewhere between these 2 calculations.
We also suggest that NPV be calculated on a per-patient ba-
sis instead of on a per-MLN basis, because decisions are
made on patients rather than on individual MLN stations.
How should the clinician decide if the EBUS-TBNA re-
sult is trustworthy? Our proposed algorithm takes into
consideration the pretest probability of N2 disease as well
as the true NPV. This algorithm may help guide clinicians
in the safe application of EBUS-TBNA evaluation of
patients with NSCLC. In our opinion, EBUS-TBNA can
accurately and minimally invasively stage up to 85% of ap-
propriately selected patients with NSCLC.WHO SHOULD DO IT?
The EBUS-TBNA operator—either a thoracic surgeon or
an interventional pulmonologist—should be an active
member of a multidisciplinary lung cancer care team.ery c September 2012
FIGURE 1. A, Algorithm for the use of endobronchial ultrasonography with transbronchial needle aspiration biopsy (EBUS-TBNA) as a staging modality
in patients with non–small cell lung cancer (NSCLC) based on pretest probability of disease by imaging. Diagnostic approach in patients with normal com-
puted tomographic (CT) imaging stratified by high (Figure 1, B) and low (Figure 1, C) probability of disease. B, High-probability normal computed tomo-
graphic (CT) scan. CT scan andmatching positron emission tomographic/computed tomographic (PET-CT) scan images of a patient with a centrally located,
intensely PET-positive right upper lobe adenocarcinoma and a radiologically normal mediastinum. In such a patient, a cytologically adequate endobronchial
ultrasonogram with a transbronchial needle aspiration biopsy (EBUS-TBNA) sample that is negative for cancer should be verified with surgical biopsy. C,
Low-probability normal computed tomographic (CT) scan. CT scan of a patient with a less than 2-cm left upper lobe non–small cell lung cancer (NSCLC)
and normal-appearing mediastinal lymph nodes in 4L. Inasmuch as the probability of N2 disease is low, a cytologically adequate endobronchial ultraso-
nography with transbronchial needle aspiration biopsy (EBUS-TBNA) that is negative for malignancy can be accepted with minimal concern for a false
negative result.
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institutional culture and physician availability. However,
the institutional practice should be in line with the purpose
of the multidisciplinary lung cancer care team: to optimize
patient care and properly allocate resources.
Optimization of Patient Care
The optimization of NSCLC treatment is a matter of pro-
viding timely and streamlined patient care.8 BecauseThe Journal of Thoracic and CaEBUS-TBNA is generally performed in the initial stages
of the evaluation of a patient with NSCLC, the timeliness
of EBUS-TBNA sets the stage for subsequent therapy.
When ROSE is available, patients can be divided into 2 ba-
sic groups: patients who are likely to need solely EBUS-
TBNA and no other procedure and patients who are likely
to require an additional procedure pending the immediate
(ROSE) results of EBUS-TBNA. In the latter group, any
additional diagnostic or therapeutic procedures (eg,rdiovascular Surgery c Volume 144, Number 3 S11
FIGURE 2. A, Approach to patients with abnormal computed tomographic/positron emission tomographic (CT/PET) imaging and either high (Figure 2, B)
or low (Figure 2, C) probability of malignancy. B, High-probability abnormal computed tomographic (CT) scan. CT scan and matching positron emission
tomographic/computed tomographic (PET-CT) scan images of a patient with cytologically confirmed N2 metastases in stations 4R and 7, but endobronchial
ultrasonography with transbronchial needle aspiration biopsy (EBUS-TBNA) samples from 4L revealed normal lymphocytes. A surgical biopsy is recom-
mended to confirm that 4L is indeed negative. C, Low-probability abnormal computed tomographic (CT) scan. CT scan and matching positron emission
tomographic/computed tomographic (PET-CT) scan images of a patient with a mildly PET-positive left upper lobe non–small cell lung cancer (NSCLC)
and diffusely enlarged, partially calcified, PET-positive mediastinal lymph nodes (MLNs) that also involve the opposite hilum. In this patient the mediastinal
findings could be explained by granulomatous disease; an endobronchial ultrasonogram with transbronchial needle aspiration biopsy (EBUS-TBNA) sample
that demonstrates granulomatous disease would be trustworthy. However, samples with only normal lymphocytes or nondiagnostic samples should prompt
the operator to pursue a surgical biopsy.
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access for chemotherapy) can be performed in the same
anesthetic setting to further streamline patient care. In our
experience, roughly 50% of patients who undergo
EBUS-TBNA have an additional procedure performed in
the same setting.7S12 The Journal of Thoracic and Cardiovascular SurgResource Allocation
Resource allocation is a key factor in the proper delivery
of health care. Although we do not have data directly com-
paring the cost of performing EBUS-TBNA in the operating
room versus in the bronchoscopy suite (regardless of type of
anesthesia), performing EBUS-TBNA in the bronchoscopyery c September 2012
Andrade et al Session I: Lung Cancer Diagnosis and Stagingsuite probably consumes less time and personnel (and hence
is less costly) than in the operating room. As a stand-alone
procedure, EBUS-TBNA would be best performed in the
bronchoscopy suite. However, if ROSE is available and
the patient is likely to require an additional procedure on
the basis of immediate results of EBUS-TBNA, then per-
forming EBUS-TBNA in the operating room could be logis-
tically and financially prudent.
Who Should Do It?
So long as the person who performs EBUS-TBNA is
a member of the multidisciplinary lung cancer care team,
has a thorough understanding of NSCLC, and is familiar
with the individual patient’s clinical situation, the issue of
thoracic surgeon versus interventional pulmonologist as op-
erator is irrelevant. The primary advantage of a thoracic sur-
geon performing EBUS as a staging procedure is the ability
to perform any other procedure if necessary at the same set-
ting, whether diagnostic or therapeutic.
In our opinion, if EBUS-TBNA is performed in the bron-
choscopy suite as a stand-alone procedure, the interven-
tional pulmonologist would be the preferred operator.
However, if EBUS-TBNA is performed on a patient who
is likely to require an additional procedure, it should ideally
be performed by the thoracic surgeon in the operating
theater.
CONCLUSIONS
When performed by committed and well-trained
physicians, EBUS-TBNA can accurately and minimallyThe Journal of Thoracic and Cainvasively stage the mediastinum in up to 85% of appropri-
ately selected patients with NSCLC. The EBUS physician,
regardless of specialty, must be a member of the multidisci-
plinary lung cancer care team, must have a thorough under-
standing of NSCLC, and must be familiar with the
individual patient’s clinical situation.References
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